M&A
confidence high
sentiment neutral
materiality 0.75
XOMA Royalty Corp (XOMA): M&A transaction — XOMA Royalty closes acquisition of Generation Bio for $4.2913/share plus CVR
XOMA Royalty Corp
- Completed tender offer; 4,722,533 shares (approx. 70%) tendered, all accepted.
- Acquisition closed Feb 9, 2026; Generation Bio becomes wholly owned subsidiary.
- CVRs entitle holders to 70-100% of Net Cash Excess and tiered shares of Legacy Assets and Moderna Collaboration proceeds.
- Binney Lease arrangement allocates up to $30M for future lease payments; excess may flow to CVR holders.
- Legacy Assets Transaction Proceeds range from 70% (Year 1-2) to 30% (Year 7-10) of Net Proceeds.